Envoy Medical Regains Compliance with Nasdaq Listing Requirement
Rhea-AI Summary
Envoy Medical (NASDAQ: COCH) announced it has regained compliance with Nasdaq Listing Rule 5550(b) after demonstrating alternatives under the rule to meet the minimum Market Value of Listed Securities. The company said strategic financing initiatives substantially strengthened its balance sheet and enabled compliance.
Envoy noted it received a Nasdaq non-compliance notice on February 25, 2025 and believes it has an achievable plan to maintain continued listing on the Nasdaq Capital Market under the symbol COCH.
Positive
- Regained compliance with Nasdaq Listing Rule 5550(b)
- Implemented strategic financing that strengthened the balance sheet
- Company states an achievable plan to maintain Nasdaq listing
Negative
- Received Nasdaq non-compliance notice on February 25, 2025 for MVLS below $35 million
Market Reaction – COCH
Following this news, COCH has gained 4.87%, reflecting a moderate positive market reaction. The stock is currently trading at $0.73. This price movement has added approximately $3M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
COCH was down 2% while sector peers were mixed (e.g., VVOS -4.4%, RBOT -7.33%, IINN +2.68%). Only one peer (TRIB, -11.38%) appeared in momentum scans, suggesting stock-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Patent portfolio update | Positive | -2.0% | Three new patents strengthening fully implanted cochlear implant IP. |
| Feb 19 | Financing & trial update | Positive | -6.3% | Upsized $30M financing and solid progress in pivotal Acclaim trial. |
| Feb 17 | Clinical trial progress | Positive | +14.8% | Pivotal trial 80% enrolled with clear PMA submission timeline. |
| Feb 12 | Offering closing | Negative | -20.5% | Closing of upsized public offering with significant new share issuance. |
| Feb 11 | Offering pricing | Negative | +69.2% | Pricing of discounted upsized equity and warrant offering. |
Recent COCH news has produced mixed reactions: positive clinical and IP updates often saw selling, while an offering pricing release triggered a sharp gain.
Over the past weeks, Envoy Medical has combined financing, clinical, and IP milestones. An upsized offering priced on Feb 11, 2026 led to a 69.2% move, while the closing announcement on Feb 12 saw a 20.52% decline. Subsequent clinical trial progress and a $30.0M financing update on Feb 19 were followed by a 6.29% drop. New patents on Feb 23 coincided with a 2% decline. Against this backdrop, today’s Nasdaq compliance confirmation continues a period of frequent, market-moving catalysts.
Market Pulse Summary
This announcement confirms Envoy Medical has regained compliance with Nasdaq’s $35 million Market Value of Listed Securities requirement, resolving a previously disclosed deficiency. It follows recent equity financings, a pivotal trial update for the Acclaim implant, and new patent grants. Investors may focus on whether balance-sheet improvements and clinical milestones are sufficient to sustain listing standards, alongside ongoing going-concern disclosures and the impact of prior share issuances.
Key Terms
listing rule 5550(b) regulatory
market value of listed securities regulatory
nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b).
As previously disclosed, the Company received a notice from Nasdaq on February 25, 2025, indicating that it was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (MVLS) of
The Company believes it has an achievable plan to maintain compliance and looks forward to remaining listed on the Nasdaq Capital Market under the symbol "COCH."
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain additional patents and develop future products or product improvements; the ability to maintain compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and the amount of capital required to complete the FDA pivotal trial and early commercialization; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submission to the FDA; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285020
FAQ
What did Envoy Medical (COCH) announce about Nasdaq compliance on February 24, 2026?
Why was Envoy Medical (COCH) previously non-compliant with Nasdaq listing rules?
How did Envoy Medical (COCH) regain compliance with Nasdaq rules?
Will Envoy Medical (COCH) remain listed on the Nasdaq Capital Market?
What does the Nasdaq compliance notice mean for Envoy Medical shareholders (COCH)?
